215 related articles for article (PubMed ID: 18030005)
21. Neoadjuvant chemotherapy in breast cancer: what questions remain?
Sulpher J; Dent R; Dent S
Curr Opin Support Palliat Care; 2014 Mar; 8(1):59-63. PubMed ID: 24407017
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
[TBL] [Abstract][Full Text] [Related]
23. When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial.
De Rossi C; Brunello A; Jirillo G; Jirillo A
Immunopharmacol Immunotoxicol; 2009 Mar; 31(1):30-1. PubMed ID: 21054206
[TBL] [Abstract][Full Text] [Related]
24. [Neoadjuvant systemic therapy in breast cancer].
Kahán Z; Nikolényi A; Uhercsák G; Thurzó L
Orv Hetil; 2009 Jan; 150(2):65-71. PubMed ID: 19103557
[TBL] [Abstract][Full Text] [Related]
25. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
[TBL] [Abstract][Full Text] [Related]
26. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment.
Bardakci M; Karakas H; Bayram D; Avci N; Kitapli S; Ozen M; Aslan F; Koseoglu C; Kadioglu A; Onur ID; Sakalar T; Buyuksimsek M; Alkan A; Ergun Y; Kaya AO; Bilgin B; Yalcin B
Sci Rep; 2024 May; 14(1):10632. PubMed ID: 38724585
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
Del Mastro L; Bighin C; Bini G; Giraudi S; Taveggia P; Levaggi A; Canavese G; Rescinito G; Pronzato P
Ann Oncol; 2010 Jun; 21(6):1376-1377. PubMed ID: 20430904
[No Abstract] [Full Text] [Related]
34. Efficacy of the CMFVP regimen in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Grenader T
Onkologie; 2012; 35(1-2):24-6. PubMed ID: 22310341
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
Anticancer Drugs; 2011 Feb; 22(2):128-35. PubMed ID: 21218604
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study.
Dodiya HG; Brahmbhatt AP; Khatri PK; Kaushal AM; Vijay DG
J Cancer Res Ther; 2015; 11(3):612-6. PubMed ID: 26458590
[TBL] [Abstract][Full Text] [Related]
37. Can we abandon anthracyclines for early breast cancer patients?
Henderson IC
Oncology (Williston Park); 2011 Feb; 25(2):115-24, 127. PubMed ID: 21456382
[TBL] [Abstract][Full Text] [Related]
38. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
39. [Adjuvant chemotherapy for breast cancer--a current controversy].
Jinno H; Ikeda T; Kubouchi K; Fujiwara K; Kitajima M
Gan To Kagaku Ryoho; 2004 Feb; 31(2):176-80. PubMed ID: 14997747
[TBL] [Abstract][Full Text] [Related]
40. Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?
Alkan A; Sahin U; Altundag K
Med Oncol; 2010 Dec; 27(4):1430. PubMed ID: 19876779
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
